Fiscal Year:
1991
Title:
IL-2 LIPOSOMES AS DELIVERY AGENTS FOR IMMUNOTHERAPEUTICS
Agency:
HHS
Contract:
N/A
Award Amount:
$47,838.00
Abstract:
VESTAR HAS DEVELOPED A LIPOSOMAL DRUG DELIVERY SYSTEM COMPRISED OF (MTX) ENCAPSULATED IN THE INTERNAL AQUEOUS SPACE OF SMALL UNILAMELLAR VESICLES AND HUMAN RECOMBINANT IL-2 COVALENTLY COUPLED TO THE EXTERIOR SURFACE. THE COMPLEX IS CALLED SUV-MTX-IL-2 (SMI). IT IS DESIGNED TO TARGET TO THE HIGH AFFINITY IL-2 RECEPTOR OF ABERRANTLY ACTIVATED T CELLS THAT PARTICIPATE IN GRAFT REJECTION AND SEVERAL AUTOIMMUNE DISORDERS. IN VITRO STUDIES AT VESTAR HAS SHOWN THAT THIS DRUG DELIVERY SYSTEM PRIMES ACTIVATED HUMAN PBL TO PROLIFERATE DUE TO THE IL-2 PRESENT AND THEN INHIBITS FURTHER GROWTH OF PROLIFERATING T CELLS DUE TO THE PRESENCE OF (MTX) TRANSPORTED INTO THE CYTOPLASM. THE GOAL OF THIS STUDY WILL BE TO SHOW THAT SMI INHIBITS THE GROWTH OF ANTIGEN-SPECIFIC T CELLS IN OXAZOLANONE-INDUCED DELAYED HYPERSENSITIVITY PRODUCED IN RATS. SMI IS PREPARED WITH A NOVEL TECHNOLOGY DESIGNED TO PROTECT THE IL-2 RECEPTOR BINDING DOMAIN ON IL-2, AND THE METHODOLOGIES USED CAN BE SCALED UP TO PREPARE STERILE SMI WHICH EXHIBITS ADEQUATE STABILITY DURING STORAGE. THE COMMERCIAL OBJECTIVE IS TO DEVELOP A LIPOSOMAL PRODUCT WHICH TARGETS AN ANTIPROLIFERATIVE DRUG TO UNWANTED CELLS OF THE IMMUNE SYSTEM WHILE MINIMIZING THE TOXICITY THAT IS CURRENTLY ASSOCIATED WITH THE FREE DRUG.
Principal Investigator:
Konigsberg, Paula J
Principal Investigator
7143944167
Business Contact:
1 r43 ai31287-01
Small Business Information at Submission:
Vestar, Inc
650 Cliffside Drive San Dimas, CA 91773
EIN/Tax ID:
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No